{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T13:23:43Z","timestamp":1774358623432,"version":"3.50.1"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,24]]},"DOI":"10.7759\/cureus.105761","type":"journal-article","created":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T12:44:32Z","timestamp":1774356272000},"source":"Crossref","is-referenced-by-count":0,"title":["A Comparative Study of Autologous Stem Cell Transplantation (ASCT) Versus No ASCT in Newly Diagnosed Multiple Myeloma: A Single-Institution Experience From South India"],"prefix":"10.7759","author":[{"given":"Victor","family":"Mondal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anand Praveen","family":"Kumar A","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abhinaya","family":"Sivaraman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prabhat","family":"Ranjan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steve","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25791","article-title":"Multiple myeloma: 2020 update on diagnosis, risk-stratification and management","volume":"95","author":"Rajkumar SV","year":"2020","unstructured":"Rajkumar SV. Multiple myeloma: 2020 update on diagnosis, risk-stratification and management. Am J Hematol. 2020, 95:548-67. 10.1002\/ajh.25791","journal-title":"Am J Hematol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar SV","year":"2014","unstructured":"Rajkumar SV, Dimopoulos MA, Palumbo A, et al.. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014, 15:e538-48. 10.1016\/S1470-2045(14)70442-5","journal-title":"Lancet Oncol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.2128","article-title":"Global burden of multiple myeloma: a systematic analysis for the Global Burden of Disease Study 2016","volume":"4","author":"Cowan AJ","year":"2018","unstructured":"Cowan AJ, Allen C, Barac A, et al.. Global burden of multiple myeloma: a systematic analysis for the Global Burden of Disease Study 2016. JAMA Oncol. 2018, 4:1221-7. 10.1001\/jamaoncol.2018.2128","journal-title":"JAMA Oncol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.canep.2019.02.010","article-title":"Distribution of multiple myeloma in India: heterogeneity in incidence across age, sex and geography","volume":"59","author":"Bora K","year":"2019","unstructured":"Bora K. Distribution of multiple myeloma in India: heterogeneity in incidence across age, sex and geography. Cancer Epidemiol. 2019, 59:215-20. 10.1016\/j.canep.2019.02.010","journal-title":"Cancer Epidemiol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2017.46","article-title":"Multiple myeloma","volume":"3","author":"Kumar SK","year":"2017","unstructured":"Kumar SK, Rajkumar V, Kyle RA, et al.. Multiple myeloma. Nat Rev Dis Primers. 2017, 3:17046. 10.1038\/nrdp.2017.46","journal-title":"Nat Rev Dis Primers"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199607113350204","article-title":"A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Fran\u00e7ais du My\u00e9lome","volume":"335","author":"Attal M","year":"1996","unstructured":"Attal M, Harousseau JL, Stoppa AM, et al.. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Fran\u00e7ais du My\u00e9lome. N Engl J Med. 1996, 335:91-7. 10.1056\/NEJM199607113350204","journal-title":"N Engl J Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa022340","article-title":"High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma","volume":"348","author":"Child JA","year":"2003","unstructured":"Child JA, Morgan GJ, Davies FE, et al.. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med. 2003, 348:1875-83. 10.1056\/NEJMoa022340","journal-title":"N Engl J Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020005288","article-title":"Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial","volume":"136","author":"Voorhees PM","year":"2020","unstructured":"Voorhees PM, Kaufman JL, Laubach J, et al.. Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial. Blood. 2020, 136:936-45. 10.1182\/blood.2020005288","journal-title":"Blood"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2204925","article-title":"Triplet therapy, transplantation, and maintenance until progression in myeloma","volume":"387","author":"Richardson PG","year":"2022","unstructured":"Richardson PG, Jacobus SJ, Weller EA, et al.. Triplet therapy, transplantation, and maintenance until progression in myeloma. N Engl J Med. 2022, 387:132-47. 10.1056\/NEJMoa2204925","journal-title":"N Engl J Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00535-0","article-title":"Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial","volume":"22","author":"Gay F","year":"2021","unstructured":"Gay F, Musto P, Rota-Scalabrini D, et al.. Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial. Lancet Oncol. 2021, 22:p1705-20. 10.1016\/S1470-2045(21)00535-0","journal-title":"Lancet Oncol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.14740\/wjon1780","article-title":"Multiple myeloma: a review of the literature and a case report highlighting the immunocompromised state of myeloma patients","volume":"15","author":"Nightingale B","year":"2024","unstructured":"Nightingale B, Decker M, Ryan R, et al.. Multiple myeloma: a review of the literature and a case report highlighting the immunocompromised state of myeloma patients. World J Oncol. 2024, 15:348-54. 10.14740\/wjon1780","journal-title":"World J Oncol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1007\/s12288-025-02221-6","article-title":"Time to autologous stem cell transplant in multiple myeloma patients: a real-world single centre experience from India [in press]","author":"Menon A","year":"2025","unstructured":"Menon A, Nair CK, Shoaib Nawaz PN, Raghavan V, Devi N, Shenoy PK. Time to autologous stem cell transplant in multiple myeloma patients: a real-world single centre experience from India [in press]. Indian J Hematol Blood Transfus. 2025, 10.1007\/s12288-025-02221-6","journal-title":"Indian J Hematol Blood Transfus"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar S","year":"2016","unstructured":"Kumar S, Paiva B, Anderson KC, et al.. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016, 17:e328-46. 10.1016\/S1470-2045(16)30206-6","journal-title":"Lancet Oncol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1007\/s12288-017-0776-1","article-title":"Cost-effectiveness of autologous stem cell treatment as compared to conventional chemotherapy for treatment of multiple myeloma in India","volume":"33","author":"Prinja S","year":"2017","unstructured":"Prinja S, Kaur G, Malhotra P, Jyani G, Ramachandran R, Bahuguna P, Varma S. Cost-effectiveness of autologous stem cell treatment as compared to conventional chemotherapy for treatment of multiple myeloma in India. Indian J Hematol Blood Transfus. 2017, 33:31-40. 10.1007\/s12288-017-0776-1","journal-title":"Indian J Hematol Blood Transfus"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.72.6679","article-title":"Lenalidomide maintenance after autologous stem-cell transplantation in newly diagnosed multiple myeloma: a meta-analysis","volume":"35","author":"McCarthy PL","year":"2017","unstructured":"McCarthy PL, Holstein SA, Petrucci MT, et al.. Lenalidomide maintenance after autologous stem-cell transplantation in newly diagnosed multiple myeloma: a meta-analysis. J Clin Oncol. 2017, 35:3279-89. 10.1200\/JCO.2017.72.6679","journal-title":"J Clin Oncol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1114138","article-title":"Lenalidomide maintenance after stem-cell transplantation for multiple myeloma","volume":"366","author":"Attal M","year":"2012","unstructured":"Attal M, Lauwers-Cances V, Marit G, et al.. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N Engl J Med. 2012, 366:1782-91. 10.1056\/NEJMoa1114138","journal-title":"N Engl J Med"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-06-858613","article-title":"Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma","volume":"132","author":"Perrot A","year":"2018","unstructured":"Perrot A, Lauwers-Cances V, Corre J, et al.. Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma. Blood. 2018, 132:2456-64. 10.1182\/blood-2018-06-858613","journal-title":"Blood"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.69.2517","article-title":"Depth of response in multiple myeloma: a pooled analysis of three PETHEMA\/GEM clinical trials","volume":"35","author":"Lahuerta JJ","year":"2017","unstructured":"Lahuerta JJ, Paiva B, Vidriales MB, et al.. Depth of response in multiple myeloma: a pooled analysis of three PETHEMA\/GEM clinical trials. J Clin Oncol. 2017, 35:2900-10. 10.1200\/JCO.2016.69.2517","journal-title":"J Clin Oncol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15143687","article-title":"Minimal residual disease in multiple myeloma: past, present, and future","volume":"15","author":"Medina-Herrera A","year":"2023","unstructured":"Medina-Herrera A, Sarasquete ME, Jim\u00e9nez C, Puig N, Garc\u00eda-Sanz R. Minimal residual disease in multiple myeloma: past, present, and future. Cancers (Basel). 2023, 15:3687. 10.3390\/cancers15143687","journal-title":"Cancers (Basel)"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1158\/2767-9764.CRC-23-0185","article-title":"Clinical benefit of autologous stem cell transplantation for patients with multiple myeloma achieving undetectable minimal residual disease after induction treatment","volume":"3","author":"Liu J","year":"2023","unstructured":"Liu J, Yan W, Fan H, et al.. Clinical benefit of autologous stem cell transplantation for patients with multiple myeloma achieving undetectable minimal residual disease after induction treatment. Cancer Res Commun. 2023, 3:1770-80. 10.1158\/2767-9764.CRC-23-0185","journal-title":"Cancer Res Commun"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/371708-a-comparative-study-of-autologous-stem-cell-transplantation-asct-versus-no-asct-in-newly-diagnosed-multiple-myeloma-a-single-institution-experience-from-south-india","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T12:44:34Z","timestamp":1774356274000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/371708-a-comparative-study-of-autologous-stem-cell-transplantation-asct-versus-no-asct-in-newly-diagnosed-multiple-myeloma-a-single-institution-experience-from-south-india"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,24]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.105761","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3,24]]}}}